Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Chondroitin Sulfate market by Type (Capsule form, Tablet form, Powder form), by Sources (Bovine, Poultry, Porcine, Shark and Fish, Others) and by End users (Pet food and veterinary supplements, Pharmaceutical and biotech companies, Cosmetics and personal care, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A08189

Pages: NA

Charts: NA

Tables: NA

Chondroitin sulfate also called as glycosaminoglycan sulfated glucose (GAG). Chondroitin sulfate is composed of long chain of alternating sugars including N-acetylga-lactosamine and glucuronic acid. This chemical compound is an essential component of the extracellular matrix made of many connective tissues, including bone, cartilage, tendons and ligaments. Chondroitin sulfate is commercially produced from various animal sources consisting pig, chicken, bovine, fish, shark, crocodiles and other animals. Chondroitin sulfate is recommended as a therapeutic intervention in multi-faceted treatment of Osteoarthritis management. It has shown positive outcomes in osteoarthritis of the finger, knee, hip joints, low back, facial joints and other diseases as it possesses anti-inflammatory properties and aids by offering resistance to compression, reduces pain in sore muscles and maintaining the structural integrity. Commercial applications continuously being explored in genetic engineering of biological tissues to accelerate the regeneration of damaged structure. It is an approved supplement in the U.S. for treatment of osteoarthritis. Regular intake of chondroitin sulfate contributes to smooth joint activities and enhanced joint function and applications extending to veterinary use.

COVID – 19 scenario analysis:  

  • The COVID-19 pandemic has emerged as a humanitarian as well as economic crisis, creating strain on the society and affecting millions of people and businesses
  • Industry closures and people are asked to stay in their homes which has cause taken a huge toll in terms of money and economic growth
  • Over 4 million people affected globally, with 300 thousand losing their lives due to novel coronavirus
  • Healthcare organizations are already working in battle mode, preparing new plans to respond growing COVID-19 patients, right from sourcing rapid diagnosing kits to sufficient PPE kits for workers
  • Due to diversion of medical field towards treating COVID-19, the funding to R&D activities related to chondroitin sulfate has been reduced and this segment have to face negligence subsequently causing negative impact on chondroitin sulfate market

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis

The rising number of patients suffering with osteoarthritis, extensive use of chondroitin sulfate in the treatment of osteoarthritis and various other ailments, wide range of application and growing demand for chondroitin sulfate in pharmaceutical industry are the key factors that would drive the market growth in years to come.  The other uses like thickeners, additives, preservatives and hygiene foods in dietary supplements and meat products in the form of sodium chondroitin sulphate, its extensive use in veterinary and animal feed due to its attribute to cure joint pain and arthritis in animals as well are further fueling the chondroitin sulfate market growth. The use of chondroitin sulphate in animal feed is further presenting a promising opportunity.

Developing economies like the U.S., United Kingdom, Germany and others have adopted chondroitin sulphate and is expected to have a positive impact on the market. Arthritis Research U.K., stated by 2035, around 8.3 million people belonging to age group 45 years and above could have knee osteoarthritis in UK. Favorable laws, increasing healthcare spending, advanced health infrastructure, increasing R&D operations in advanced countries are expected to surge the demand for chondroitin sulfate.

However, several side effects due to direct inhalation such as nausea, heartburn, diarrhoea and constipation would hamper the growth. In addition, tablets of chondroitin sulfate contain manganese in amounts which can cause hazardous effects on the body. These factors would cause hindrance in the market.

Rising incidences of osteoarthritis and wide applicability of chondroitin sulfate to propel market growth

The incidence of osteoarthritis is one of the major factors to fuel the market growth. 8.9 fractures are caused by osteoarthritis annually in the U.S. As per National Arthritis Statistics of U.S., in the year, around 55.6 million U.S. adults were diagnosed with some form of arthritis, gout, lupus, rheumatoid arthritis. The product chondroitin sulfate due to its attribute of slowing down the breakdown of cartilages and reduction in muscle pain, it is extensively used in treatment of osteoporosis thereby increasing the demand for the product all over the world. Chondroitin sulfate is used an alternative therapy in integration with several other drugs and therapies for treating osteoarthritis, cataracts and urinary tract infections as well as solution for preserving corneas used for transplants. Chondroitin sulfate orally consumed for treating HIV/AIDS, coronary diseases, heart ailments, flaky skin (psoriasis) and muscle soreness which are expected to surge the overall product demand during the forecast period.  It is usually used in combination with glucosamine to treat Osteoarthritis. Regulation of cell development, cell adhesion, proliferation, and differentiation are the key functions where chondroitin plays key role. It can also be used to enhance digestive function, improve the liver functioning, reduce blood sugar level and prevent tumor. Lotions, ointments and pharmaceutical infusions consisting of chondroitin sulfate are likewise utilized by individuals suffering from osteoarthritis. Around 20 million people are suffering from joint related ailments in the U.S. alone which would create immense opportunities of growth for chondroitin sulfate market. While as per AIHW in 2014-15, osteoarthritis affected more than 9% of the Australian population.

Rising demand in animal feed industry

Chondroitin sulfate is an essential bio-supplement in the animal feed industry as its consumption can help animals in avoiding and treating problems related to arthritis or hip dysplasia. Besides, it has several other health benefits. Veterinary supplements and animal feeds extensively include Chondroitin sulfate due to its health benefits. Chondroitin sulfate also aids in keeping pets active and healthy with as they ensure better joint mobility and functioning. For example, Zeria Group (ZPD) offers  a variety of several concentrations like different grades containing 20%, 40%, and 80% chondroitin sulfate for the manufacturers of pet food in accordance with the industry requirements.

Key benefits of the report:

  • This study presents the analytical depiction of the global chondroitin sulfate industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global chondroitin sulfate market share.
  • The current market is quantitatively analysed to highlight the global chondroitin sulfate market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed global chondroitin sulfate market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the Chondroitin Sulfate Market research report:

  • Who are the leading market players active in the chondroitin sulfate market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the chondroitin sulfate market?
  • What are the projections for the future that will help in taking further strategic steps?

Key Market Segments

  • By Type
    • Capsule form
    • Tablet form
    • Powder form
  • By Sources
    • Bovine
    • Poultry
    • Porcine
    • Shark and Fish
    • Others
  • By End users
    • Pet food and veterinary supplements
    • Pharmaceutical and biotech companies
    • Cosmetics and personal care
    • Others
  • By Region
    • North America
      • US
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • UK
      • Italy
      • Spain
      • rest of Europe
    • Asia-Pacific
      • Japan
      • China
      • India
      • Australia
      • South Korea
      • rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Arabia
      • South Arica
      • rest of LAMEA


Key Market Players

  • S.A.U. Seikagaku Corporation
  • Yantai Ruikangda Biochemical Products
  • Pacific Rainbow International
  • Shandong Runxin Biotechnology
  • Sioux Pharm
  • Synutra Ingredients
  • Bioiberica.
  • Summit Nutritionals International
  • TSI Group
  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: CHONDROITIN SULFATE MARKET, BY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Type

    • 4.2. Capsule Form

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Tablet Form

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Powder Form

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

  • CHAPTER 5: CHONDROITIN SULFATE MARKET, BY SOURCES

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Sources

    • 5.2. Bovine

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Poultry

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Porcine

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Shark And Fish

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Others

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

  • CHAPTER 6: CHONDROITIN SULFATE MARKET, BY END USERS

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End Users

    • 6.2. Pet Food And Veterinary Supplements

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Pharmaceutical And Biotech Companies

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Cosmetics And Personal Care

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Others

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

  • CHAPTER 7: CHONDROITIN SULFATE MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Type

      • 7.2.3. Market Size and Forecast, By Sources

      • 7.2.4. Market Size and Forecast, By End Users

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Chondroitin Sulfate Market

        • 7.2.6.1. Market Size and Forecast, By Type
        • 7.2.6.2. Market Size and Forecast, By Sources
        • 7.2.6.3. Market Size and Forecast, By End Users
      • 7.2.7. Canada Chondroitin Sulfate Market

        • 7.2.7.1. Market Size and Forecast, By Type
        • 7.2.7.2. Market Size and Forecast, By Sources
        • 7.2.7.3. Market Size and Forecast, By End Users
      • 7.2.8. Mexico Chondroitin Sulfate Market

        • 7.2.8.1. Market Size and Forecast, By Type
        • 7.2.8.2. Market Size and Forecast, By Sources
        • 7.2.8.3. Market Size and Forecast, By End Users
    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Type

      • 7.3.3. Market Size and Forecast, By Sources

      • 7.3.4. Market Size and Forecast, By End Users

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Chondroitin Sulfate Market

        • 7.3.6.1. Market Size and Forecast, By Type
        • 7.3.6.2. Market Size and Forecast, By Sources
        • 7.3.6.3. Market Size and Forecast, By End Users
      • 7.3.7. Germany Chondroitin Sulfate Market

        • 7.3.7.1. Market Size and Forecast, By Type
        • 7.3.7.2. Market Size and Forecast, By Sources
        • 7.3.7.3. Market Size and Forecast, By End Users
      • 7.3.8. Italy Chondroitin Sulfate Market

        • 7.3.8.1. Market Size and Forecast, By Type
        • 7.3.8.2. Market Size and Forecast, By Sources
        • 7.3.8.3. Market Size and Forecast, By End Users
      • 7.3.9. Spain Chondroitin Sulfate Market

        • 7.3.9.1. Market Size and Forecast, By Type
        • 7.3.9.2. Market Size and Forecast, By Sources
        • 7.3.9.3. Market Size and Forecast, By End Users
      • 7.3.10. UK Chondroitin Sulfate Market

        • 7.3.10.1. Market Size and Forecast, By Type
        • 7.3.10.2. Market Size and Forecast, By Sources
        • 7.3.10.3. Market Size and Forecast, By End Users
      • 7.3.11. Russia Chondroitin Sulfate Market

        • 7.3.11.1. Market Size and Forecast, By Type
        • 7.3.11.2. Market Size and Forecast, By Sources
        • 7.3.11.3. Market Size and Forecast, By End Users
      • 7.3.12. Rest Of Europe Chondroitin Sulfate Market

        • 7.3.12.1. Market Size and Forecast, By Type
        • 7.3.12.2. Market Size and Forecast, By Sources
        • 7.3.12.3. Market Size and Forecast, By End Users
    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Type

      • 7.4.3. Market Size and Forecast, By Sources

      • 7.4.4. Market Size and Forecast, By End Users

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Chondroitin Sulfate Market

        • 7.4.6.1. Market Size and Forecast, By Type
        • 7.4.6.2. Market Size and Forecast, By Sources
        • 7.4.6.3. Market Size and Forecast, By End Users
      • 7.4.7. Japan Chondroitin Sulfate Market

        • 7.4.7.1. Market Size and Forecast, By Type
        • 7.4.7.2. Market Size and Forecast, By Sources
        • 7.4.7.3. Market Size and Forecast, By End Users
      • 7.4.8. India Chondroitin Sulfate Market

        • 7.4.8.1. Market Size and Forecast, By Type
        • 7.4.8.2. Market Size and Forecast, By Sources
        • 7.4.8.3. Market Size and Forecast, By End Users
      • 7.4.9. South Korea Chondroitin Sulfate Market

        • 7.4.9.1. Market Size and Forecast, By Type
        • 7.4.9.2. Market Size and Forecast, By Sources
        • 7.4.9.3. Market Size and Forecast, By End Users
      • 7.4.10. Australia Chondroitin Sulfate Market

        • 7.4.10.1. Market Size and Forecast, By Type
        • 7.4.10.2. Market Size and Forecast, By Sources
        • 7.4.10.3. Market Size and Forecast, By End Users
      • 7.4.11. Thailand Chondroitin Sulfate Market

        • 7.4.11.1. Market Size and Forecast, By Type
        • 7.4.11.2. Market Size and Forecast, By Sources
        • 7.4.11.3. Market Size and Forecast, By End Users
      • 7.4.12. Malaysia Chondroitin Sulfate Market

        • 7.4.12.1. Market Size and Forecast, By Type
        • 7.4.12.2. Market Size and Forecast, By Sources
        • 7.4.12.3. Market Size and Forecast, By End Users
      • 7.4.13. Indonesia Chondroitin Sulfate Market

        • 7.4.13.1. Market Size and Forecast, By Type
        • 7.4.13.2. Market Size and Forecast, By Sources
        • 7.4.13.3. Market Size and Forecast, By End Users
      • 7.4.14. Rest of Asia Pacific Chondroitin Sulfate Market

        • 7.4.14.1. Market Size and Forecast, By Type
        • 7.4.14.2. Market Size and Forecast, By Sources
        • 7.4.14.3. Market Size and Forecast, By End Users
    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Type

      • 7.5.3. Market Size and Forecast, By Sources

      • 7.5.4. Market Size and Forecast, By End Users

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Chondroitin Sulfate Market

        • 7.5.6.1. Market Size and Forecast, By Type
        • 7.5.6.2. Market Size and Forecast, By Sources
        • 7.5.6.3. Market Size and Forecast, By End Users
      • 7.5.7. South Africa Chondroitin Sulfate Market

        • 7.5.7.1. Market Size and Forecast, By Type
        • 7.5.7.2. Market Size and Forecast, By Sources
        • 7.5.7.3. Market Size and Forecast, By End Users
      • 7.5.8. Saudi Arabia Chondroitin Sulfate Market

        • 7.5.8.1. Market Size and Forecast, By Type
        • 7.5.8.2. Market Size and Forecast, By Sources
        • 7.5.8.3. Market Size and Forecast, By End Users
      • 7.5.9. UAE Chondroitin Sulfate Market

        • 7.5.9.1. Market Size and Forecast, By Type
        • 7.5.9.2. Market Size and Forecast, By Sources
        • 7.5.9.3. Market Size and Forecast, By End Users
      • 7.5.10. Argentina Chondroitin Sulfate Market

        • 7.5.10.1. Market Size and Forecast, By Type
        • 7.5.10.2. Market Size and Forecast, By Sources
        • 7.5.10.3. Market Size and Forecast, By End Users
      • 7.5.11. Rest of LAMEA Chondroitin Sulfate Market

        • 7.5.11.1. Market Size and Forecast, By Type
        • 7.5.11.2. Market Size and Forecast, By Sources
        • 7.5.11.3. Market Size and Forecast, By End Users
  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning, 2024

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Shandong Runxin Biotechnology

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Synutra Ingredients

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Yantai Ruikangda Biochemical Products

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. TSI Group

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. S.A.U. Seikagaku Corporation

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Sioux Pharm

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Pacific Rainbow International

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Summit Nutritionals International

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Bioiberica.

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL CHONDROITIN SULFATE MARKET, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL CHONDROITIN SULFATE MARKET FOR CAPSULE FORM, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL CHONDROITIN SULFATE MARKET FOR TABLET FORM, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL CHONDROITIN SULFATE MARKET FOR POWDER FORM, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL CHONDROITIN SULFATE MARKET, BY SOURCES, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL CHONDROITIN SULFATE MARKET FOR BOVINE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL CHONDROITIN SULFATE MARKET FOR POULTRY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL CHONDROITIN SULFATE MARKET FOR PORCINE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL CHONDROITIN SULFATE MARKET FOR SHARK AND FISH, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL CHONDROITIN SULFATE MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL CHONDROITIN SULFATE MARKET, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL CHONDROITIN SULFATE MARKET FOR PET FOOD AND VETERINARY SUPPLEMENTS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL CHONDROITIN SULFATE MARKET FOR PHARMACEUTICAL AND BIOTECH COMPANIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL CHONDROITIN SULFATE MARKET FOR COSMETICS AND PERSONAL CARE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. GLOBAL CHONDROITIN SULFATE MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. GLOBAL CHONDROITIN SULFATE MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 17. NORTH AMERICA CHONDROITIN SULFATE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 18. NORTH AMERICA CHONDROITIN SULFATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 19. NORTH AMERICA CHONDROITIN SULFATE, BY SOURCES, 2025-2033 ($MILLION)
  • TABLE 20. NORTH AMERICA CHONDROITIN SULFATE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 21. U.S. CHONDROITIN SULFATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 22. U.S. CHONDROITIN SULFATE, BY SOURCES, 2025-2033 ($MILLION)
  • TABLE 23. U.S. CHONDROITIN SULFATE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 24. CANADA CHONDROITIN SULFATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 25. CANADA CHONDROITIN SULFATE, BY SOURCES, 2025-2033 ($MILLION)
  • TABLE 26. CANADA CHONDROITIN SULFATE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 27. MEXICO CHONDROITIN SULFATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 28. MEXICO CHONDROITIN SULFATE, BY SOURCES, 2025-2033 ($MILLION)
  • TABLE 29. MEXICO CHONDROITIN SULFATE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 30. EUROPE CHONDROITIN SULFATE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 31. EUROPE CHONDROITIN SULFATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 32. EUROPE CHONDROITIN SULFATE, BY SOURCES, 2025-2033 ($MILLION)
  • TABLE 33. EUROPE CHONDROITIN SULFATE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 34. FRANCE CHONDROITIN SULFATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 35. FRANCE CHONDROITIN SULFATE, BY SOURCES, 2025-2033 ($MILLION)
  • TABLE 36. FRANCE CHONDROITIN SULFATE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 37. GERMANY CHONDROITIN SULFATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 38. GERMANY CHONDROITIN SULFATE, BY SOURCES, 2025-2033 ($MILLION)
  • TABLE 39. GERMANY CHONDROITIN SULFATE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 40. ITALY CHONDROITIN SULFATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 41. ITALY CHONDROITIN SULFATE, BY SOURCES, 2025-2033 ($MILLION)
  • TABLE 42. ITALY CHONDROITIN SULFATE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 43. SPAIN CHONDROITIN SULFATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 44. SPAIN CHONDROITIN SULFATE, BY SOURCES, 2025-2033 ($MILLION)
  • TABLE 45. SPAIN CHONDROITIN SULFATE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 46. UK CHONDROITIN SULFATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 47. UK CHONDROITIN SULFATE, BY SOURCES, 2025-2033 ($MILLION)
  • TABLE 48. UK CHONDROITIN SULFATE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 49. RUSSIA CHONDROITIN SULFATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 50. RUSSIA CHONDROITIN SULFATE, BY SOURCES, 2025-2033 ($MILLION)
  • TABLE 51. RUSSIA CHONDROITIN SULFATE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 52. REST OF EUROPE CHONDROITIN SULFATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 53. REST OF EUROPE CHONDROITIN SULFATE, BY SOURCES, 2025-2033 ($MILLION)
  • TABLE 54. REST OF EUROPE CHONDROITIN SULFATE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 55. ASIA-PACIFIC CHONDROITIN SULFATE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 56. ASIA-PACIFIC CHONDROITIN SULFATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 57. ASIA-PACIFIC CHONDROITIN SULFATE, BY SOURCES, 2025-2033 ($MILLION)
  • TABLE 58. ASIA-PACIFIC CHONDROITIN SULFATE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 59. CHINA CHONDROITIN SULFATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 60. CHINA CHONDROITIN SULFATE, BY SOURCES, 2025-2033 ($MILLION)
  • TABLE 61. CHINA CHONDROITIN SULFATE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 62. JAPAN CHONDROITIN SULFATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 63. JAPAN CHONDROITIN SULFATE, BY SOURCES, 2025-2033 ($MILLION)
  • TABLE 64. JAPAN CHONDROITIN SULFATE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 65. INDIA CHONDROITIN SULFATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 66. INDIA CHONDROITIN SULFATE, BY SOURCES, 2025-2033 ($MILLION)
  • TABLE 67. INDIA CHONDROITIN SULFATE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 68. SOUTH KOREA CHONDROITIN SULFATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 69. SOUTH KOREA CHONDROITIN SULFATE, BY SOURCES, 2025-2033 ($MILLION)
  • TABLE 70. SOUTH KOREA CHONDROITIN SULFATE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 71. AUSTRALIA CHONDROITIN SULFATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 72. AUSTRALIA CHONDROITIN SULFATE, BY SOURCES, 2025-2033 ($MILLION)
  • TABLE 73. AUSTRALIA CHONDROITIN SULFATE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 74. THAILAND CHONDROITIN SULFATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 75. THAILAND CHONDROITIN SULFATE, BY SOURCES, 2025-2033 ($MILLION)
  • TABLE 76. THAILAND CHONDROITIN SULFATE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 77. MALAYSIA CHONDROITIN SULFATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 78. MALAYSIA CHONDROITIN SULFATE, BY SOURCES, 2025-2033 ($MILLION)
  • TABLE 79. MALAYSIA CHONDROITIN SULFATE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 80. INDONESIA CHONDROITIN SULFATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 81. INDONESIA CHONDROITIN SULFATE, BY SOURCES, 2025-2033 ($MILLION)
  • TABLE 82. INDONESIA CHONDROITIN SULFATE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 83. REST OF ASIA PACIFIC CHONDROITIN SULFATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 84. REST OF ASIA PACIFIC CHONDROITIN SULFATE, BY SOURCES, 2025-2033 ($MILLION)
  • TABLE 85. REST OF ASIA PACIFIC CHONDROITIN SULFATE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 86. LAMEA CHONDROITIN SULFATE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 87. LAMEA CHONDROITIN SULFATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 88. LAMEA CHONDROITIN SULFATE, BY SOURCES, 2025-2033 ($MILLION)
  • TABLE 89. LAMEA CHONDROITIN SULFATE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 90. BRAZIL CHONDROITIN SULFATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 91. BRAZIL CHONDROITIN SULFATE, BY SOURCES, 2025-2033 ($MILLION)
  • TABLE 92. BRAZIL CHONDROITIN SULFATE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 93. SOUTH AFRICA CHONDROITIN SULFATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 94. SOUTH AFRICA CHONDROITIN SULFATE, BY SOURCES, 2025-2033 ($MILLION)
  • TABLE 95. SOUTH AFRICA CHONDROITIN SULFATE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 96. SAUDI ARABIA CHONDROITIN SULFATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 97. SAUDI ARABIA CHONDROITIN SULFATE, BY SOURCES, 2025-2033 ($MILLION)
  • TABLE 98. SAUDI ARABIA CHONDROITIN SULFATE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 99. UAE CHONDROITIN SULFATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 100. UAE CHONDROITIN SULFATE, BY SOURCES, 2025-2033 ($MILLION)
  • TABLE 101. UAE CHONDROITIN SULFATE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 102. ARGENTINA CHONDROITIN SULFATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 103. ARGENTINA CHONDROITIN SULFATE, BY SOURCES, 2025-2033 ($MILLION)
  • TABLE 104. ARGENTINA CHONDROITIN SULFATE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 105. REST OF LAMEA CHONDROITIN SULFATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 106. REST OF LAMEA CHONDROITIN SULFATE, BY SOURCES, 2025-2033 ($MILLION)
  • TABLE 107. REST OF LAMEA CHONDROITIN SULFATE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 108. SHANDONG RUNXIN BIOTECHNOLOGY: KEY EXECUTIVES
  • TABLE 109. SHANDONG RUNXIN BIOTECHNOLOGY: COMPANY SNAPSHOT
  • TABLE 110. SHANDONG RUNXIN BIOTECHNOLOGY: OPERATING SEGMENTS
  • TABLE 111. SHANDONG RUNXIN BIOTECHNOLOGY: PRODUCT PORTFOLIO
  • TABLE 112. SHANDONG RUNXIN BIOTECHNOLOGY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 113. SYNUTRA INGREDIENTS: KEY EXECUTIVES
  • TABLE 114. SYNUTRA INGREDIENTS: COMPANY SNAPSHOT
  • TABLE 115. SYNUTRA INGREDIENTS: OPERATING SEGMENTS
  • TABLE 116. SYNUTRA INGREDIENTS: PRODUCT PORTFOLIO
  • TABLE 117. SYNUTRA INGREDIENTS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 118. YANTAI RUIKANGDA BIOCHEMICAL PRODUCTS: KEY EXECUTIVES
  • TABLE 119. YANTAI RUIKANGDA BIOCHEMICAL PRODUCTS: COMPANY SNAPSHOT
  • TABLE 120. YANTAI RUIKANGDA BIOCHEMICAL PRODUCTS: OPERATING SEGMENTS
  • TABLE 121. YANTAI RUIKANGDA BIOCHEMICAL PRODUCTS: PRODUCT PORTFOLIO
  • TABLE 122. YANTAI RUIKANGDA BIOCHEMICAL PRODUCTS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 123. TSI GROUP: KEY EXECUTIVES
  • TABLE 124. TSI GROUP: COMPANY SNAPSHOT
  • TABLE 125. TSI GROUP: OPERATING SEGMENTS
  • TABLE 126. TSI GROUP: PRODUCT PORTFOLIO
  • TABLE 127. TSI GROUP: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 128. S.A.U. SEIKAGAKU CORPORATION: KEY EXECUTIVES
  • TABLE 129. S.A.U. SEIKAGAKU CORPORATION: COMPANY SNAPSHOT
  • TABLE 130. S.A.U. SEIKAGAKU CORPORATION: OPERATING SEGMENTS
  • TABLE 131. S.A.U. SEIKAGAKU CORPORATION: PRODUCT PORTFOLIO
  • TABLE 132. S.A.U. SEIKAGAKU CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 133. SIOUX PHARM: KEY EXECUTIVES
  • TABLE 134. SIOUX PHARM: COMPANY SNAPSHOT
  • TABLE 135. SIOUX PHARM: OPERATING SEGMENTS
  • TABLE 136. SIOUX PHARM: PRODUCT PORTFOLIO
  • TABLE 137. SIOUX PHARM: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 138. PACIFIC RAINBOW INTERNATIONAL: KEY EXECUTIVES
  • TABLE 139. PACIFIC RAINBOW INTERNATIONAL: COMPANY SNAPSHOT
  • TABLE 140. PACIFIC RAINBOW INTERNATIONAL: OPERATING SEGMENTS
  • TABLE 141. PACIFIC RAINBOW INTERNATIONAL: PRODUCT PORTFOLIO
  • TABLE 142. PACIFIC RAINBOW INTERNATIONAL: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 143. SUMMIT NUTRITIONALS INTERNATIONAL: KEY EXECUTIVES
  • TABLE 144. SUMMIT NUTRITIONALS INTERNATIONAL: COMPANY SNAPSHOT
  • TABLE 145. SUMMIT NUTRITIONALS INTERNATIONAL: OPERATING SEGMENTS
  • TABLE 146. SUMMIT NUTRITIONALS INTERNATIONAL: PRODUCT PORTFOLIO
  • TABLE 147. SUMMIT NUTRITIONALS INTERNATIONAL: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 148. BIOIBERICA.: KEY EXECUTIVES
  • TABLE 149. BIOIBERICA.: COMPANY SNAPSHOT
  • TABLE 150. BIOIBERICA.: OPERATING SEGMENTS
  • TABLE 151. BIOIBERICA.: PRODUCT PORTFOLIO
  • TABLE 152. BIOIBERICA.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • LIST OF FIGURES

  • FIGURE 1. GLOBAL CHONDROITIN SULFATE MARKET SEGMENTATION
  • FIGURE 2. GLOBAL CHONDROITIN SULFATE MARKET
  • FIGURE 3. SEGMENTATION CHONDROITIN SULFATE MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN CHONDROITIN SULFATE MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALCHONDROITIN SULFATE MARKET
  • FIGURE 11. CHONDROITIN SULFATE MARKET SEGMENTATION, BY BY TYPE
  • FIGURE 12. CHONDROITIN SULFATE MARKET FOR CAPSULE FORM, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. CHONDROITIN SULFATE MARKET FOR TABLET FORM, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. CHONDROITIN SULFATE MARKET FOR POWDER FORM, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. CHONDROITIN SULFATE MARKET SEGMENTATION, BY BY SOURCES
  • FIGURE 16. CHONDROITIN SULFATE MARKET FOR BOVINE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. CHONDROITIN SULFATE MARKET FOR POULTRY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. CHONDROITIN SULFATE MARKET FOR PORCINE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. CHONDROITIN SULFATE MARKET FOR SHARK AND FISH, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. CHONDROITIN SULFATE MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. CHONDROITIN SULFATE MARKET SEGMENTATION, BY BY END USERS
  • FIGURE 22. CHONDROITIN SULFATE MARKET FOR PET FOOD AND VETERINARY SUPPLEMENTS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. CHONDROITIN SULFATE MARKET FOR PHARMACEUTICAL AND BIOTECH COMPANIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 24. CHONDROITIN SULFATE MARKET FOR COSMETICS AND PERSONAL CARE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 25. CHONDROITIN SULFATE MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 26. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 27. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 28. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 29. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 30. COMPETITIVE DASHBOARD
  • FIGURE 31. COMPETITIVE HEATMAP: CHONDROITIN SULFATE MARKET
  • FIGURE 32. TOP PLAYER POSITIONING, 2024
  • FIGURE 33. SHANDONG RUNXIN BIOTECHNOLOGY: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 34. SHANDONG RUNXIN BIOTECHNOLOGY: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 35. SHANDONG RUNXIN BIOTECHNOLOGY: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 36. SYNUTRA INGREDIENTS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 37. SYNUTRA INGREDIENTS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 38. SYNUTRA INGREDIENTS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 39. YANTAI RUIKANGDA BIOCHEMICAL PRODUCTS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 40. YANTAI RUIKANGDA BIOCHEMICAL PRODUCTS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 41. YANTAI RUIKANGDA BIOCHEMICAL PRODUCTS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 42. TSI GROUP: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 43. TSI GROUP: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 44. TSI GROUP: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 45. S.A.U. SEIKAGAKU CORPORATION: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 46. S.A.U. SEIKAGAKU CORPORATION: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 47. S.A.U. SEIKAGAKU CORPORATION: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 48. SIOUX PHARM: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 49. SIOUX PHARM: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 50. SIOUX PHARM: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 51. PACIFIC RAINBOW INTERNATIONAL: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 52. PACIFIC RAINBOW INTERNATIONAL: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 53. PACIFIC RAINBOW INTERNATIONAL: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 54. SUMMIT NUTRITIONALS INTERNATIONAL: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 55. SUMMIT NUTRITIONALS INTERNATIONAL: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 56. SUMMIT NUTRITIONALS INTERNATIONAL: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 57. BIOIBERICA.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 58. BIOIBERICA.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 59. BIOIBERICA.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Chondroitin Sulfate market by Type

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue